CCL9/10/MIP-1 gamma Antibody (62105) [Unconjugated]

Mouse CCL9/10/MIP 1 gamma Antibody Clone # 62105 (Catalog # MAB463) neutralizes CCL9/10/MIP-1 gamma (463-MG) induced chemotaxis in the BaF3 mouse pro-B cell line transfected with human CCR1. The Neutralization Dose (ND50) for this effect is typically 1.50-15.0 µg/mL in the presence of 1.00 μg/mL Recombinant Mouse CCL9/10/MIP-1 gamma .

• Reactivity: Mu
• Applications: WB, B/N, ELISA(Cap)
• Clone: 62105
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Unconjugated

CCL9/10/MIP-1 gamma Antibody (62105) [Unconjugated] Summary

• Immunogen: E. coli-derived recombinant mouse CCL9/10/MIP‑1 gamma
  Gln22-Gln122
  Accession # P51670
• Specificity: Detects mouse CCL9/10/MIP‑1 gamma in ELISAs and Western blots. In sandwich ELISAs, less than 0.02% cross-reactivity with recombinant human CCL3, 4, 15, 19, 20, recombinant mouse CCL3, 4, 19, or recombinant rat CCL20 is observed.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Rat
• Gene: Ccl9
• Purity Statement: Protein A or G purified from hybridoma culture supernatant
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • ELISA Capture (Matched Antibody Pair) 2-8 ug/mL
  • ELISA Detection (Matched Antibody Pair) 0.1-0.4 ug/mL
  • ELISA Standard (Matched Pair)
  • Neutralization 1-4 ug/mL
  • Western Blot 1 ug/mL
• Application Notes: ELISA Detection: Mouse CCL9/10/MIP-1gamma Biotinylated Antibody (Catalog number BAF463)
  Standard: Recombinant Mouse CCL9/10/MIP-1gamma (Catalog number 463-MG)

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.
  *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CCL9/10/MIP-1 gamma Antibody (62105) [Unconjugated]

• C-C motif chemokine 9
• CCF18
• CCL9/10
• chemokine (C-C motif) ligand 9
• macrophage inflammatory protein 1-gamma
• macrophage inflammatory protein-related protein 2
• MIP1 gamma
• MIP-1 gamma
• MRP-2
• SCYA10
• Scya9
• small inducible cytokine A10
• small inducible cytokine A9

Background

Mouse CCL9/10 (also named MIP-1 gamma and MRP-2) is an 11 kDa, secreted, monomeric polypeptide that belongs to the beta (or CC) intercrine family of chemokines (1‑3). Based on its activity and amino acid (aa) sequence, it is further classified as a member of the NC6 or six cysteine-containing CC subfamily of chemokines (2, 4, 5). This subfamily contains four N-terminally extended chemokines, two human (CCL15 and CCL23) and two mouse (CCL9 and CCL10). Within this subfamily, there are no human-to-rodent interspecies orthologs. Mouse CCL9/10 is synthesized as a 122 aa precursor that contains a 21 aa signal sequence and a 101 aa mature region with six cysteines. As noted, the mature region has an expanded N-terminus relative to other CC family members, and it forms a third intrachain disulfide bond with its two extra cysteines (3‑7). Mouse CCL9/10 is 75% aa identical to rat CCL9/10 (8). Chemokines are known to undergo proteolytic processing to generate multiple isoforms. NC6 chemokines are usually only marginally active at full‑length, but are converted to highly active forms upon N-terminal truncation. Mature CCL9, in the presence of inflammatory fluids, is naturally truncated by 28, 29 or 30 aa at the N-terminus, generating a highly active, 8 kDa, 71‑73 aa CCR1 ligand. In contrast, other CCR1 ligands, CCL3/MIP-1 alpha and CCL5/RANTES, lose their potency when proteolytically processed. CCL9/10 is constitutively secreted, and circulates as a full‑length molecule. Any onset of inflammation with subsequent enzyme release may act on local NC6 chemokines, generating early, potent leukocyte chemoattractants (5, 7).

1. Zlotnik, A. and O. Yoshie (2000) Immunity 12:121.
2. Zlotnik, A. et al. (1999) Crit. Rev. Immunol. 19:1
3. Mohamadzadeh, M. et al. (1996) J. Immunol. 156:3102.
4. Haelens, A. et al. (1996) Immunobiology 195:499.
5. Berahovich, R.D. et al. (2005) J. Immunol. 174:7341.
6. Youn, B-S. et al. (1995) J. Immunol. 155:2661.
7. Poltorak, A.N. et al. (1995) J. Inflamm. 45:207.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for CCL9/10/MIP-1 gamma Antibody (MAB463)(8)

Publications using MAB463

• C Hemmers, C Schulte, J Wollenhaup, DWL Wong, E Harlacher, S Orth-Alamp, BM Klinkhamme, SH Schirmer, M Böhm, N Marx, T Speer, P Boor, J Jankowski, H Noels Chemokine CCL9 Is Upregulated Early in Chronic Kidney Disease and Counteracts Kidney Inflammation and Fibrosis Biomedicines, 2022-02-10;10(2):. 2022-02-10 [PMID: 35203629] (Neutralization, Mouse)
• Jorge Luis Galeano Niño, Sophie V Pageon, Szun S Tay, Feyza Colakoglu, Daryan Kempe, Jack Hywood et al. Cytotoxic T cells swarm by homotypic chemokine signalling eLife 2020-10-13 [PMID: 33046212]
• L Li, L Ni, RF Heary, S Elkabes Astroglial TLR9 antagonism promotes chemotaxis and alternative activation of macrophages via modulation of astrocyte-derived signals: implications for spinal cord injury J Neuroinflammation, 2020-02-25;17(1):73. 2020-02-25 [PMID: 32098620] (Neutralization, Mouse)
• R Chen, Y Xie, X Zhong, Y Fu, Y Huang, Y Zhen, P Pan, H Wang, DL Bartlett, TR Billiar, MT Lotze, HJ Zeh, XG Fan, D Tang, R Kang Novel chemokine-like activities of histones in tumor metastasis Oncotarget, 2016-09-20;7(38):61728-61740. 2016-09-20 [PMID: 27623211] (Neutralization, Human)
• Kathryn E LeMasters, Yotam Blech-Hermoni, Samantha J Stillwagon, Natalie A Vajda, Andrea N Ladd Loss of muscleblind-like 1 promotes invasive mesenchyme formation in endocardial cushions by stimulating autocrine TGF beta 3 BMC Developmental Biology 2012-12-01 [PMID: 22866814]
• Zhang M, Yin L, Zhang K, Sun W, Yang S, Zhang B, Salzman P, Wang W, Liu C, Vidyasagar S, Zhang L, Ju S, Okunieff P, Zhang L Response patterns of cytokines/chemokines in two murine strains after irradiation. Cytokine, 2012-01-25;58(2):169-77. 2012-01-25 [PMID: 22277799] (Luminex Development, Mouse)
• Okamatsu Y, Battaglino R, Spate U, Stashenko P MIP-1 gamma promotes receptor-activator-of-NF-kappa-B-ligand-induced osteoclast formation and survival. J. Immunol., 2004-08-01;173(3):2084-90. 2004-08-01 [PMID: 15265944] (Neutralization, Mouse)
• Mosmann T Synthesis of several chemokines but few cytokines by primed uncommitted precursor CD4 T cells suggests that these cells recruit other immune cells without exerting direct effector functions. Eur. J. Immunol., 2004-06-01;34(6):1617-26. 2004-06-01 [PMID: 15162431] (ELISA Development, ELISpot Development, Mouse)

Bioinformatics

• Gene Symbol: Ccl9
• Uniprot:
  • P51670()